Skip to main content
SpringerLink
Log in

SEOR SBRT-SG stereotactic body radiation therapy consensus guidelines for non-spine bone metastasis

  • Special Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

The use of stereotactic body radiation therapy (SBRT) to treat non-spine bone metastases (NSBM) is becoming increasingly common in clinical practice. The clinical advantages of SBRT include good pain control and high local control rates, although only limited data are available. The Spanish Society of Radiation Oncology (SEOR) SBRT group recently convened a task force of experts in the field to address key questions related to SBRT for NSBM, including treatment indications, planning, techniques, and dose fractionation. The task force reviewed the available literature to develop evidence-based recommendations for the safe application of NSBM SBRT and to standardize and optimize SBRT processes. The present document provides a comprehensive analysis of the available data, including ongoing clinical trials and controversies, providing clinically applicable recommendations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Steenland E, Leer JW, van Houwelingen H, Post WJ, van den Hout WB, Kievit J, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol J Eur Soc Ther Radiol Oncol. 1999;52(2):101–9. https://doi.org/10.1016/s0167-8140(99)00110-3.

    Article  CAS  Google Scholar 

  2. Roos DE, Turner SL, O’Brien PC, Smith JG, Spry NA, Burmeister BH, et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 9605). Radiother Oncol J Eur Soc Ther Radiol Oncol. 2005;75(1):54–63. https://doi.org/10.1016/j.radonc.2004.09.017.

    Article  Google Scholar 

  3. Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, et al. Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7(1):4–12. https://doi.org/10.1016/j.prro.2016.08.001.

    Article  PubMed  Google Scholar 

  4. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet (Lond Engl). 2019;393(10185):2051–8. https://doi.org/10.1016/S0140-6736(18)32487-5.

    Article  Google Scholar 

  5. Redmond KJ, Robertson S, Lo SS, Soltys SG, Ryu S, McNutt T, et al. Consensus contouring guidelines for postoperative stereotactic body radiation therapy for metastatic solid tumor malignancies to the spine. Int J Radiat Oncol Biol Phys. 2017;97(1):64–74. https://doi.org/10.1016/j.ijrobp.2016.09.014.

    Article  PubMed  Google Scholar 

  6. Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Hoyer M, Hurkmans C, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2017;124(1):11–7. https://doi.org/10.1016/j.radonc.2017.05.012.

    Article  Google Scholar 

  7. Saad F, Lipton A, Cook R, Chen Y-M, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860–7. https://doi.org/10.1002/cncr.22991.

    Article  PubMed  Google Scholar 

  8. Piccioli A, Spinelli MS, Maccauro G. Impending fracture: a difficult diagnosis. Injury. 2014;45(Suppl 6):S138–41. https://doi.org/10.1016/j.injury.2014.10.038.

    Article  PubMed  Google Scholar 

  9. Behnke NK, Baker DK, Xu S, Niemeier TE, Watson SL, Ponce BA. Risk factors for same-admission mortality after pathologic fracture secondary to metastatic cancer. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2017;25(2):513–21. https://doi.org/10.1007/s00520-016-3431-8.

    Article  Google Scholar 

  10. Ward WG, Holsenbeck S, Dorey FJ, Spang J, Howe D. Metastatic disease of the femur: surgical treatment. Clin Orthop Relat Res. 2003;415 Suppl:S230–44. https://doi.org/10.1097/01.blo.0000093849.72468.82.

    Article  Google Scholar 

  11. Howard EL, Cool P, Cribb GL. Prediction of pathological fracture in patients with metastatic disease of the lower limb. Sci Rep. 2019;9(1):14133. https://doi.org/10.1038/s41598-019-50636-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Harrington KD. Impending pathologic fractures from metastatic malignancy: evaluation and management. Instr Course Lect. 1986;35:357–81.

    CAS  PubMed  Google Scholar 

  13. Carnesale P. Malignant tumours of bone. In: St Canale JB, editor. Campbell’s operative orthopaedics. 10th ed. Amsterdam: Elsevier; 2003. p. 551.

    Google Scholar 

  14. Damron TA, Mann KA. Fracture risk assessment and clinical decision making for patients with metastatic bone disease. J Orthop Res Off Publ Orthop Res Soc. 2020;38(6):1175–90. https://doi.org/10.1002/jor.24660.

    Article  Google Scholar 

  15. Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res. 1989;249:256–64.

    Article  Google Scholar 

  16. van der Wal CWPG, Eggermont F, Fiocco M, Kroon HM, Ayu O, Slot A, et al. Axial cortical involvement of metastatic lesions to identify impending femoral fractures; a clinical validation study. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020;144:59–64. https://doi.org/10.1016/j.radonc.2019.10.007.

    Article  Google Scholar 

  17. Tatar Z, Soubrier M, Dillies AF, Verrelle P, Boisgard S, Lapeyre M. Assessment of the risk factors for impending fractures following radiotherapy for long bone metastases using CT scan-based virtual simulation: a retrospective study. Radiat Oncol. 2014;9:227. https://doi.org/10.1186/s13014-014-0227-1.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Damron TA, Nazarian A, Entezari V, Brown C, Grant W, Calderon N, et al. CT-based structural rigidity analysis is more accurate than mirels scoring for fracture prediction in metastatic femoral lesions. Clin Orthop Relat Res. 2016;474(3):643–51. https://doi.org/10.1007/s11999-015-4453-0.

    Article  PubMed  Google Scholar 

  19. West H (Jack), Jin JO. Performance Status in Patients With Cancer. JAMA Oncol 2015;1(7):998. https://doi.org/10.1001/jamaoncol.2015.3113.

  20. Nguyen Q-N, Chun SG, Chow E, Komaki R, Liao Z, Zacharia R, et al. Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial. JAMA Oncol. 2019;5(6):872–8. https://doi.org/10.1001/jamaoncol.2019.0192.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Zelefsky MJ, Yamada Y, Greco C, Lis E, Schöder H, Lobaugh S, et al. Phase 3 multi-center, prospective, randomized trial comparing single-dose 24 gy radiation therapy to a 3-fraction sbrt regimen in the treatment of oligometastatic cancer. Int J Radiat Oncol Biol Phys. 2021;110(3):672–9. https://doi.org/10.1016/j.ijrobp.2021.01.004.

    Article  PubMed  Google Scholar 

  22. Mercier C, Claessens M, Buys A, Gryshkevych S, Billiet C, Joye I, et al. Stereotactic ablative radiation therapy to all lesions in patients with oligometastatic cancers: a phase 1 dose-escalation trial. Int J Radiat Oncol Biol Phys. 2021;109(5):1195–205. https://doi.org/10.1118/1.3438081.

    Article  PubMed  Google Scholar 

  23. Somigliana A, Zonca G, Loi G, Sichirollo AE. How thick should CT/MR slices be to plan conformal radiotherapy? A study on the accuracy of three-dimensional volume reconstruction. Tumori. 1996;82(5):470–2.

    Article  CAS  PubMed  Google Scholar 

  24. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys. 2010;37(8):4078–101. https://doi.org/10.1016/j.ijrobp.2020.11.066.

    Article  PubMed  Google Scholar 

  25. Habl G, Straube C, Schiller K, Duma MN, Oechsner M, Kessel KA, et al. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer. 2017;17(1):361. https://doi.org/10.1186/s12885-017-3341-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ogawa H, Ito K, Shimizuguchi T, Furuya T, Nihei K, Karasawa K. Re-irradiation for painful bone metastases using stereotactic body radiotherapy. Acta Oncol. 2018;57(12):1700–4. https://doi.org/10.1080/0284186X.2018.1503712.

    Article  CAS  PubMed  Google Scholar 

  27. David S, Tan J, Savas P, Bressel M, Kelly D, Foroudi F, et al. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial. Breast. 2020;49:55–62. https://doi.org/10.1016/j.breast.2019.10.016.

    Article  PubMed  Google Scholar 

  28. Olson R, Liu M, Bergman A, Lam S, Hsu F, Mou B, et al. Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5. BMC Cancer. 2018;18(1):954. https://doi.org/10.1186/s12885-018-4859-7.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Owen D, Laack NN, Mayo CS, Garces YI, Park SS, Bauer HJ, et al. Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases. Pract Radiat Oncol. 2014;4(2):e143–9. https://doi.org/10.1016/j.prro.2013.05.006.

    Article  PubMed  Google Scholar 

  30. Erler D, Brotherston D, Sahgal A, Cheung P, Loblaw A, Chu W, et al. Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2018;127(2):304–9. https://doi.org/10.1016/j.radonc.2018.03.030.

    Article  Google Scholar 

  31. Yang H-L, Liu T, Wang X-M, Xu Y, Deng S-M. Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol. 2011;21(12):2604–17. https://doi.org/10.1007/s00330-011-2221-4.

    Article  PubMed  Google Scholar 

  32. Raman S, Chin L, Erler D, Atenafu EG, Cheung P, Chu W, et al. Impact of magnetic resonance imaging on gross tumor volume delineation in non-spine bony metastasis treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2018;102(4):735-743.e1. https://doi.org/10.1016/j.ijrobp.2018.03.010.

    Article  PubMed  Google Scholar 

  33. Gerlich AS, van der Velden JM, Kotte ANTJ, Tseng CL, Fanetti G, Eppinga WSC, et al. Inter-observer agreement in GTV delineation of bone metastases on CT and impact of MR imaging: a multicenter study. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2018;126(3):534–40. https://doi.org/10.1016/j.radonc.2017.08.030.

    Article  CAS  Google Scholar 

  34. Nguyen TK, Sahgal A, Dagan R, Eppinga W, Guckenberger M, Kim JH, et al. Stereotactic body radiation therapy for nonspine bone metastases: international practice patterns to guide treatment planning. Pract Radiat Oncol. 2020;10(6):e452–60. https://doi.org/10.1016/j.prro.2020.02.011.

    Article  PubMed  Google Scholar 

  35. Nguyen T, Chin L, Sahgal A, Dagan R, Eppinga W, Guckenberger M, et al. International consensus contouring recommendations for stereotactic body radiotherapy of non-spine bone metastases. Int J Radiat Oncol Biol Phys. 2020;108(3):S90. https://doi.org/10.1016/j.ijrobp.2020.07.2253.

    Article  Google Scholar 

  36. Ilamurugu A, Chandrasekaran A, Ayyalusamy A, Prasanna Satpathy S, Reddy JM, Arora S, et al. Volumetric and dosimetric impact of MRI in delineation of gross tumor volume of non-spinal vertebral metastases treated with stereotactic ablative radiation therapy. Cancer Radiother. 2021;25(2):135–40. https://doi.org/10.1016/j.canrad.2020.06.032.

    Article  CAS  PubMed  Google Scholar 

  37. van de Ven S, van den Bongard D, Pielkenrood B, Kasperts N, Eppinga W, Peters M, et al. Patient-reported outcomes of oligometastatic patients after conventional or stereotactic radiation therapy to bone metastases: an analysis of the PRESENT cohort. Int J Radiat Oncol Biol Phys. 2020;107(1):39–47. https://doi.org/10.1016/j.ijrobp.2019.12.041.

    Article  PubMed  Google Scholar 

  38. Wilson DD, Alonso CE, Sim AJ, Peck T, Handsfield LL, Chen Q, et al. STAT RT: a prospective pilot clinical trial of scan-plan-QA-treat stereotactic body radiation therapy for painful osseous metastases. Ann Palliat Med. 2019;8(3):221–30. https://doi.org/10.21037/apm.2018.12.07.

    Article  PubMed  Google Scholar 

  39. Loi M, Nuyttens JJ, Desideri I, Greto D, Livi L. Single-fraction radiotherapy (SFRT) for bone metastases: patient selection and perspectives. Cancer Manag Res. 2019;11:9397–408. https://doi.org/10.2147/CMAR.S186630.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Ito K, Shimizuguchi T, Nihei K, Furuya T, Ogawa H, Tanaka H, et al. Patterns of intraosseous recurrence after stereotactic body radiation therapy for coxal bone metastasis. Int J Radiat Oncol Biol Phys. 2018;100(1):159–61. https://doi.org/10.1093/jjco/hyaa128.

    Article  PubMed  Google Scholar 

  41. Clézardin P. Pathophysiology of bone metastases from solid malignancies. Jt Bone Spine. 2017;84(6):677–84. https://doi.org/10.1016/j.jbspin.2017.05.006.

    Article  CAS  Google Scholar 

  42. Athanassiadou P, Grapsa D. Bone marrow micrometastases in different solid tumors: pathogenesis and importance. Surg Oncol. 2008;17(3):153–64. https://doi.org/10.1016/j.suronc.2008.04.004.

    Article  PubMed  Google Scholar 

  43. Perez-Calatayud MJ, Conde-Moreno AJ, Celada-Álvarez FJ, Rubio C, López-Campos F, Navarro-Martin A, et al. SEOR SBRT-SG survey on SRS/SBRT dose prescription criteria in Spain. Clin Transl Oncol. 2021;23(9):1794–800. https://doi.org/10.1007/s12094-021-02583-z.

    Article  CAS  PubMed  Google Scholar 

  44. Gerhard SG, Palma DA, Arifin AJ, Louie AV, Li GJ, Al-Shafa F, et al. Organ at risk dose constraints in SABR: a systematic review of active clinical trials. Pract Radiat Oncol. 2021;11(4):e355–65. https://doi.org/10.1016/j.prro.2021.03.005.

    Article  PubMed  Google Scholar 

  45. Hanna GG, Murray L, Patel R, Jain S, Aitken KL, Franks KN, et al. UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol (R Coll Radiol). 2018;30(1):5–14. https://doi.org/10.1016/j.clon.2017.09.007.

    Article  CAS  Google Scholar 

  46. Bhattacharya IS, Hoskin PJ. Stereotactic body radiotherapy for spinal and bone metastases. Clin Oncol (R Coll Radiol). 2015;27(5):298–306. https://doi.org/10.1016/j.clon.2015.01.030.

    Article  CAS  Google Scholar 

  47. Jhaveri PM, Teh BS, Paulino AC, Blanco AI, Lo SS, Butler EB, et al. A dose-response relationship for time to bone pain resolution after stereotactic body radiotherapy (SBRT) for renal cell carcinoma (RCC) bony metastases. Acta Oncol. 2012;51(5):584–8. https://doi.org/10.3109/0284186X.2011.652741.

    Article  PubMed  Google Scholar 

  48. Ito K, Yamaguchi T, Ogawa H, Nakajima Y, Karasawa K. Stereotactic body radiotherapy for bone metastases in patients with colorectal cancer. Jpn J Clin Oncol. 2020;50(12):1442–6. https://doi.org/10.1093/jjco/hyaa128.

    Article  PubMed  Google Scholar 

  49. Greco C, Zelefsky MJ, Lovelock M, Fuks Z, Hunt M, Rosenzweig K, et al. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol. 2011;79(4):1151–7. https://doi.org/10.1016/j.ijrobp.2009.12.038.

    Article  Google Scholar 

  50. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol. 2012;83(3):878–86. https://doi.org/10.1016/j.ijrobp.2011.08.036.

    Article  Google Scholar 

  51. Zelefsky MJ, Greco C, Motzer R, Magsanoc JM, Pei X, Lovelock M, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1744–8. https://doi.org/10.1016/j.ijrobp.2011.02.040.

    Article  PubMed  Google Scholar 

  52. Muacevic A, Kufeld M, Rist C, Wowra B, Stief C, Staehler M. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol. 2013;31(4):455–60. https://doi.org/10.1016/j.urolonc.2011.02.023.

    Article  PubMed  Google Scholar 

  53. Berwouts D, De Wolf K, Lambert B, Bultijnck R, De Neve W, De Lobel L, et al. Biological 18[F]-FDG-PET image-guided dose painting by numbers for painful uncomplicated bone metastases: a 3-arm randomized phase II trial. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2015;115(2):272–8. https://doi.org/10.1016/j.radonc.2015.04.022.

    Article  CAS  Google Scholar 

  54. Amini A, Altoos B, Bourlon MT, Bedrick E, Bhatia S, Kessler ER, et al. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: is RCC truly radioresistant? Pract Radiat Oncol. 2015;5(6):e589–96. https://doi.org/10.1016/j.prro.2015.05.004.

    Article  PubMed  PubMed Central  Google Scholar 

  55. McDonald R, Probyn L, Poon I, Erler D, Brotherston D, Soliman H, et al. Tumor response after stereotactic body radiation therapy to nonspine bone metastases: an evaluation of response criteria. Int J Radiat Oncol Biol Phys. 2015;93(4):879–81. https://doi.org/10.1016/j.ijrobp.2015.07.2288.

    Article  PubMed  Google Scholar 

  56. Aitken K, Tree A, Thomas K, Nutting C, Hawkins M, Tait D, et al. Initial UK experience of stereotactic body radiotherapy for extracranial oligometastases: can we change the therapeutic paradigm? Clin Oncol. 2015;27(7):411–9. https://doi.org/10.1016/j.clon.2015.03.006.

    Article  CAS  Google Scholar 

  57. Napieralska A, Miszczyk L, Stapor-Fudzinska M. CyberKnife stereotactic radiosurgery and stereotactic ablative radiation therapy of patients with prostate cancer bone metastases. Neoplasma. 2016;63(2):304–12. https://doi.org/10.4149/218_150807N435.

    Article  CAS  PubMed  Google Scholar 

  58. Ursino S, Montrone S, Cantarella M, Menghini V, Matteucci F, Mazzotti V, et al. Stereotactic body radiotherapy of bone metastases in oligometastatic disease: prognostic factors of oncologic outcomes. Tumori. 2016;102(1):59–64. https://doi.org/10.5301/tj.5000441.

    Article  CAS  PubMed  Google Scholar 

  59. Ito K, Nakajima Y, Onoe T, Ogawa H, Harada H, Saito M, et al. Phase 2 clinical trial of stereotactic body radiation therapy for painful nonspine bone metastases. Pract Radiat Oncol. 2021;11(2):e139–45. https://doi.org/10.1016/j.prro.2020.10.003.

    Article  PubMed  Google Scholar 

  60. Thibault I, Chang EL, Sheehan J, Ahluwalia MS, Guckenberger M, Sohn M-J, et al. Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. Lancet Oncol. 2015;16(16):e595-603. https://doi.org/10.1016/S1470-2045(15)00166-7.

    Article  PubMed  Google Scholar 

  61. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

    Article  CAS  PubMed  Google Scholar 

  62. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(14):2942–53. https://doi.org/10.1200/JCO.2004.08.181.

    Article  Google Scholar 

  63. Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, et al. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 2010;102(4):651–7. https://doi.org/10.1038/sj.bjc.6605546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Milano MT, Philip A, Okunieff P. Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int J Radiat Oncol Biol Phys. 2009;73(3):832–7. https://doi.org/10.1016/j.ijrobp.2008.04.073.

    Article  PubMed  Google Scholar 

  65. Yu T, Choi C-W, Kim KS. Treatment outcomes of stereotactic ablative radiation therapy for non-spinal bone metastases: focus on response assessment and treatment indication. Br J Radiol. 2019;92(1099):20181048. https://doi.org/10.1259/bjr.20181048.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, et al. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys. 2012;82(5):1730–7. https://doi.org/10.1016/j.ijrobp.2011.02.008.

    Article  PubMed  Google Scholar 

  67. Gomez-Iturriaga A, Cacicedo J, Navarro A, Morillo V, Willisch P, Carvajal C, et al. Incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: multicenter prospective observational study. BMC Palliat Care. 2015;14:48. https://doi.org/10.1186/s12904-015-0045-8.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Preedy VR, Watson RR. Handbook of disease burdens and quality of life measures 2010. https://doi.org/10.1007/978-0-387-78665-0_5216

  69. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, et al. American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(23):2563–77. https://doi.org/10.1200/JCO.2015.61.6706.

    Article  Google Scholar 

  70. Wang X, Zeng M. First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332). J Clin Oncol. 2020;38(15_suppl):9508. https://doi.org/10.1200/JCO.2020.38.15_suppl.9508.

    Article  Google Scholar 

  71. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1): e173501. https://doi.org/10.1001/jamaoncol.2017.3501.

    Article  PubMed  Google Scholar 

  72. Gomez DR, Tang C, Zhang J, Blumenschein GRJ, Hernandez M, Lee JJ, et al. Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(18):1558–65. https://doi.org/10.1200/JCO.19.00201.

    Article  CAS  Google Scholar 

Download references

Funding

No funding.

Author information

Authors and Affiliations

  1. Radiation Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain

    F. Lopez-Campos

  2. Radiation Oncology Department, Osakidetza/Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Barakaldo, Spain

    J. Cacicedo

  3. Department of Surgery, Radiology and Physical Medicine of the University of the Basque Country (UPV/EHU), Vizcaya, Spain

    J. Cacicedo

  4. Radiation Oncology Department, Hospital Universitario Quirón Salud, Hospital La Luz, Madrid, Universidad Europea de Madrid (UEM), Madrid, Spain

    F. Couñago

  5. Radiation Oncology Department, Hospital Ruber Internacional Madrid, Madrid, Spain

    R. García

  6. Radiation Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain

    O. Leaman-Alcibar

  7. Radiation Oncology Department, Institut Català d’Oncologia, Hospital Duran i Reynals, Barcelona, Spain

    A. Navarro-Martin & H. Pérez-Montero

  8. Radiation Oncology Department, Hospital Universitario y Politécnico La Fe, Valencia, CEU Cardenal Herrera University, Castellón, Spain

    A. Conde-Moreno

Authors
  1. F. Lopez-Campos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Cacicedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Couñago
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. García
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. Leaman-Alcibar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Navarro-Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Pérez-Montero
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Conde-Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to this manuscript.

Corresponding author

Correspondence to F. Lopez-Campos.

Ethics declarations

Conflict of interest

Authors declare no conflict of interests for this article.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Consent to participate and publication

The manuscript has been read and approved for submission by all the named authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lopez-Campos, F., Cacicedo, J., Couñago, F. et al. SEOR SBRT-SG stereotactic body radiation therapy consensus guidelines for non-spine bone metastasis. Clin Transl Oncol 24, 215–226 (2022). https://doi.org/10.1007/s12094-021-02695-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-021-02695-6

Keywords

Search

Navigation